Hannah L Kalvin

5PUBLICATIONS
38CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 25, 2026
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma.

|Aug 13, 2026
Phase II trial of First-Line Axitinib Plus Nivolumab in Patients with Advanced Mucosal Melanoma.

|Dec 20, 2024
Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer.

Lauren E Schleimer, Emeline Aviki, Hannah L Kalvin

|May 20, 2024
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.

James W Smithy, Hannah L Kalvin, Fiona D Ehrich

|Apr 11, 2023
Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1.

Kimberly Loo, Hannah L Kalvin, Katherine S Panageas

Pageof 1

Frequent Collaborators

4 joint publications

Alexander N Shoushtari

3 joint publications

James W Smithy

3 joint publications

Michael A Postow

3 joint publications

Katherine S Panageas